



Warren and colleagues conducted a retrospective population-based study to assess the impact of tyrosine kinase inhibitors on overall survival in patients treated for metastatic renal cell carcinoma. See **page 281** for more.

Le docteur Warren et ses collaborateurs ont effectué une étude rétrospective de population afin d'évaluer l'effet des inhibiteurs de la tyrosine-kinase sur la survie globale des patients atteints d'un néphrocarcinome métastatique. Pour plus de détails, veuillez vous reporter à la **page 281**.

All editorial matter in *CUAJ* represents the opinions of the authors and not necessarily those of the Canadian Urological Association. The CUA assumes no responsibility or liability for damages arising from any error or omission or from the use of any information or advice contained in *CUAJ*.

Publications Mail Agreement no. 41387051. Return undeliverable Canadian copies to *CUAJ*, 1155 University Ave., Suite 1303, Montréal QC H3B 3A7; journal@cua.org.

Numéro de convention poste-publications 41387051. Retourner toutes copies canadiennes non livrées au *JAUC*, 1155 rue Université, Bureau 1303, Montréal QC H3B 3A7; journal@cua.org.

ISSN 1911-6470
e-ISSN 1920-1214

EDITORIAL

- 277 The editor is back**
L. Klotz

ÉDITORIAL

- 278 Retour du rédacteur en chef**
L. Klotz

CUA NEWS

- 279 CUA's strategic moves**
J.B. Gajewski

NOUVELLES DE L'AUC

- 280 Les actions stratégiques de l'AUC**
J.B. Gajewski

ORIGINAL RESEARCH

- 281 A population-based study examining the effect of tyrosine kinase inhibitors on survival in metastatic renal cell carcinoma in Alberta and the role of nephrectomy prior to treatment**
M. Warren, P.M. Venner, S. North, T. Cheng, C. Venner, S. Ghosh, A.A. Venner, D. Finch

COMMENTARY

- 292 Impact of tyrosine kinase inhibitors and cytoreductive nephrectomy in patients with metastatic renal cell carcinoma**
W. Kassouf

ORIGINAL RESEARCH

- 293 The top 100 cited articles in urology**
K. Hennessey, K. Afshar, A.E. MacNeily

COMMENTARY

- 303 On the shoulders of giants**
P.A.M. Anderson

ORIGINAL RESEARCH

- 304** Colour Doppler ultrasound hemodynamic characteristics of patients with priapism before and after therapeutic interventions
R.K. Chiou, H. Aggarwal, C.R. Chiou, F. Broughton, S. Liu

COMMENTARY

- 312** Colour duplex ultrasound and simplified corporoglanular shunting procedures with and without tunnelling in contemporary management of priapism
A.J. Bella, T.F. Lue

ORIGINAL RESEARCH

- 314** Activation of P2Y1 and P2Y2 nucleotide receptors by adenosine 5'-triphosphate analogues augmented nerve-mediated relaxation of human corpus cavernosum
S. Gur, W.J.G. Hellstrom
- 319** Optical coherence tomography: a novel modality for scrotal imaging
C. Davis, W. Kuang

REVIEW

- 323** Nonsteroidal anti-inflammatory drugs and prostate cancer: a systematic review of the literature and meta-analysis
S. Jafari, M. Etminan, K. Afshar

POINT / COUNTERPOINT

- 331** There is no role for focal therapy in prostate cancer
P. Black
- 333** Focal therapy for localized prostate cancer — choosing the middle ground
U. Lindner, J. Trachtenberg

CASE REPORTS

- 336** Listing of online case reports

IN MEMORIAM

RESOURCES

- 289** Correction
- 337** Instructions for Authors
- 338** Instructions aux auteurs
- 345** Prescribing Index
- 350** Urology Meetings of Interest
- 351** Calendar of CME Events

ADVERTISERS' INDEX / INDEX DES ANNONCEURS

AMS Canada Inc.

Inside back cover

AstraZeneca Canada Inc.

Zoladex LA Inside front cover, 345

Clarion Medical Technologies Inc.

274

Merck Frosst Canada Ltd.

Proscar 290-1, 346-7

Purdue Pharma Inc.

Uromax 348-9, Outside back cover